Login
$SION
$3.12 +$0.00 (0.0%) After hours

$SION SEC Filings

Filed On Filing
10 Nov 2026 10-Q
10 Nov 2026 8-K: Results of Operations and Financial Condition

Advancing SION-451 + SION-2222 dual combination to AscenSION CF Phase 2 proof-of-concept trial, expected to initiate in the first quarter of 2027

09 Nov 2026 SCHEDULE 13G
21 Sep 2026 SCHEDULE 13D/A
21 Sep 2026 Form 4: Ra Capital MANAGEMENT, L.p., Director and 5 others

Sold 3,448,811 shares ($21.8M)

18 Sep 2026 Form 4: Ridloff Elena, CFO and CBO

Received 94,537 shares as a grant or award · Granted 165,440 Non-Qualified Stock Option (right to buy) · Disposed of 165,440 Non-Qualified Stock Option (right to buy) (Disposition to Issuer)

18 Sep 2026 Form 4: McKee Charlotte, CMO and Head of R&D

Received 100,000 shares as a grant or award · Granted 155,700 Non-Qualified Stock Option (right to buy) · Disposed of 155,700 Non-Qualified Stock Option (right to buy) (Disposition to Issuer)

18 Sep 2026 Form 4: Fitzpatrick Jennifer, CLO and Head of Program Mgmt.

Received 56,265 shares as a grant or award · Granted 103,140 Non-Qualified Stock Option (right to buy) · Disposed of 103,140 Non-Qualified Stock Option (right to buy) (Disposition to Issuer)

18 Sep 2026 Form 4: Cloonan Michael, Director

Received 218,050 shares as a grant or award · Granted 436,100 Non-Qualified Stock Option (right to buy) · Disposed of 436,100 Non-Qualified Stock Option (right to buy) (Disposition to Issuer)

17 Sep 2026 144
14 Sep 2026 8-K: Costs Associated with Exit or Disposal Activities; Departure/Election of Directors or Officers; Compensation +1 more

Post hoc analyses of SION-719 PreciSION CF subset showed a mean placebo-adjusted sweat chloride

10 Aug 2026 8-K: Other Events

SION-719 Phase 2a proof-of-concept trial did not achieve key activity endpoint of sweat chloride reduction when added to standard of care; Company is not advancing SION-719 as an add-on to standard of care

06 Aug 2026 10-Q
06 Aug 2026 8-K: Results of Operations and Financial Condition

PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care is on track for topline data summer of 2026

09 Jul 2026 Form 4: Orbimed Advisors Llc, Director and 1 other

Sold 85,918 shares ($3.85M)

09 Jul 2026 Form 4: Thompson Peter A., Director

Sold 85,918 shares ($3.85M)

07 Jul 2026 Form 4: Fitzpatrick Jennifer, Chief Legal Officer

Received 10,250 shares by exercise or conversion ($62.6K) · Sold 10,250 shares ($447K)

06 Jul 2026 144
02 Jul 2026 Form 4: Orbimed Advisors Llc, Director and 1 other

Sold 115,844 shares ($5.27M)

02 Jul 2026 Form 4: Thompson Peter A., Director

Sold 115,844 shares ($5.27M)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support